Prevalence of insulin resistance in relation to body weight - Importance for primary prevention of cardiovascular diseases;Prävalenz der insulinresistenz in abhängigkeit vom körpergewicht - Bedeutung für die primärprävention kardiovaskulärer erkrankungen

Geburtshilfe und Frauenheilkunde

Volumn 66, Issue 3, 2006, Pages 284-293

  Moltz, Lothar ^a  

^a Institut für Präventive Medizin   (Germany)

Author keywords

Cardiovascular diseases; Glucose and insulin determination; Insulin resistance; Oral tolerance test of glucose; Primary prevention

Indexed keywords

GLUCOSE; INSULIN;

ARTICLE; BODY WEIGHT; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; FEMALE; HUMAN; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; METABOLIC SYNDROME X; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; ORAL GLUCOSE TOLERANCE TEST; PREVALENCE;

EID: 33646457654     PISSN: 00165751     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2006-924019     Document Type: Article

References (71)

1. Reaven GM. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-1607
2. Dunaif A, Segal KR, Futterweit W, Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 1989; 38: 1165-1174
3. Yip J, Facchini FS, Reaven GM. Resistance to insulin-mediated glucose disposal as a predictor of cardiovascular disease. JCEM 1998; 83: 2773-2776
4. Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Cardiovascular risk factors clustering with endogenous hyperinsulinaemia predict death from coronary heart disease in patients with type II diabetes. Diabetologia 2000; 43: 148-155
5. Yeni-Komshian H, Carantoni M, Abbasi F, Reaven GM. Relationship between several surrogate estimates of insulin resistance and quantification of insulin-mediated glucose disposal in 490 healthy nondiabetic volunteers. Diabetes Care 2000; 23: 171-175
6. Facchini FS, Hua N, Abbasi F, Reaven GM. Insulin resistance as a predictor of age-related diseases. JCEM 2001; 86: 3574-3578
7. Bergmann RN. Editorial: Insulin action and distribution of tissue blood flow. JCEM 2003; 88: 4556-4558
8. McLaughlin T, Abbasi F, Cheal K, Chu J, Lamendola C, Reaven GM. Use of metabolic markers to identify overweight individuals who are insulin resistent. Ann Intern Med 2003; 139: 802-809
9. Reaven GM. Insulin resistance/compensatory hyperinsulinemia, essential hypertension, and cardiovascular disease. JCEM 2003; 88: 2399-2403
10. Kronmal RA, Barzilay JI, Tracy RP, Savage PJ, Orchard TJ, Burke GL. The relationship of fasting serum radioimmune insulin levels to incident coronary heart disease in an insulin-treated diabetic cohort. JCEM 2004; 89: 2852-2858
11. Reaven GM. The metabolic syndrome or the insulin resistance syndrome? Different names, different concepts, and different goals. Endocrinol Metab Clin N Am 2004; 33: 283-303
12. Reaven GM. The insulin resistance syndrome: definition and dietary approaches to treatment. Annu Rev Nutr 2005; 25: 17.1-17.16
13. Despres JP, Lamarche B, Mauriege P, Bernard C, Gilles D, Sital M, Lupien PJ. Hyperinsulinemia as an independent risk factor for ischemic heart disease. NEJM 1996; 334: 952-957
14. Zavaroni I, Bonini P, Gasparini AL, Barilli A, Zuccarelli E, Dall'Aglio E, Delsignore R, Reaven GM. Hyperinsulinemia in a normal population as a predictor of non-insulin-dependent diabetes mellitus, hypertension, and coronary heart disease: the Barilla factory revisited. Metabolism 1999; 48: 989-994
15. Bonora E, Kiechl S, Willeit J, Oberhollenzer F, Egger G, Targher G, Alberiche M, Bonadonna RC, Muggeo M. Prevalence of insulin resistance in metabolic disorders: the Bruneck Study. Diabetes 1998; 47: 1643-1649
16. Karelis AD, Pierre DHS, Conus F, Rabasa-Lhoret R, Poehlman ET. Metabolic and body composition factors in subgroups of obesity. What do we know? JCEM 2004; 89: 2569-2575
17. McLaughlin T, Allison G, Abbasi F, Lamendola C, Reaven GM. Prevalence of insulin resistance and associated cardiovascular disease risk factors among normal weight, overweight, and obese individuals. Metabolism 2004; 53: 495-499
18. Alberti KGMM, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Diabet Med 1998; 15: 539-553
19. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419
20. Katz A, Nambi SS, Mather K et al. Quantitative insulin sensitivity check index: a simple, accurate methode for assessing insulin sensitivity in humans. JCEM 2000; 85: 2402-2410
21. Bergmann RN, Ader M, Huecking K, Van Citters G. Accurate assessment of β-cell function: the hyperbolic correction. Diabetes 2002; 51: S212-220
22. Quon MJ. Editorial: Limitations of the fasting glucose to insulin ratio as an index of insulin sensitivity. JCEM 2001; 86: 4615-4617
23. Abbassi F, Reaven GM. Evaluation of the quantitative insulin sensitivity check index as an estimate of insulin sensitivity in humans. Metabolism 2002; 51: 235-237
24. Diamanti-Kandarakis E, Kouli C, Alexandraki K, Spina G. Failure of mathematical indices to accurately assess insulin resistance in lean, overweight, or obese women with polycystic ovary syndrome. JCEM 2004; 89: 1273-1276
25. De Fronzo RA, Tobin JD, Andres R. Glucose clamp technique. A method for quantifying insulin secretion and resistance. Am J Physiol 1979; 237: E214-E223
26. Bergmann RN, Ider YZ, Bowden CR, Cobelli C. Quantitative estimation of insulin sensitivity. Am J Physiol 1979; 236: E667-E677
27. Isomaa B, Almgren P, Tuomi T, Forsén B, Lahti K, Nissén M, Taskinen MR, Groop L. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001; 24: 683-689
28. Bonora E, Targher G, Alberich M, Bonadonna RC, Saggiani F, Zenere MB, Monauni T, Muggeo M. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity. Diabetes Care 2000; 23: 57-63
29. ATP III. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment panel III). JAMA 2001; 285: 2486-2497
30. Assmann G, Cullen P, Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the Prospective Cardiovascular Münster (PROCAM) Study. Circulation 2002; 105: 310-315
31. Gutt M, Davis CL, Spitzer SB, Llabre MM, Kumar M, Czarnecki EM, Schneiderman N, Skyler JS, Marks JB. Validation of the insulin sensitivity index (ISLO, 120):comparison with other measures. Diabetes Research and Clinical Practice 2000; 47: 177-184
32. Haffner SM, Miettinen H, Stern MP. The homeostasis model in the San Antonio Heart Study. Diabetes Care 1997; 20: 1087-1092
33. Cree MG, Newcomer BR, Katsanos CS, Sheddield M, Chinkes D, Aarsland A, Urban R, Wolfe RR. Intramuscular and liver triglycerides are increased in the elderly. JCEM 2003; 89: 3864-3871
34. Ostlund RE, Staten M, Kortt WM, Schultz DJ, Malley M. The ratio of waist-to-hip circumference, plasma insulin level, and glucose intolerance as independent predictors of the HDL2-Cholesterol level in older adults. NEJM 1990; 322: 29-34
35. Laakso M. How good a marker is insulin level for insulin resistance? Am J Epidemol 1993; 137: 959-965
36. Forst T, Standl E, Hohberg C, Konradt T, Schulze J, Strotmann HJ, Lübbens G, Pahler S, Bachinger A, Langenfeld M, Pfützner A. IRIS II study: the IRIS II score-assessment of a new clinical algorithm for the classification of insulin resistance in patients with type 2 diabetes. Diabetes UK. Diabetic Medicine 2004; 21: 1149-1153
37. Mykhänen L, Laakso M, Pyörälä K. High plasma insulin level associated with coronary heart disease in the elderly. Am J Epidemiol 1993; 137: 1190-1202
38. Geisthövel F. Persönliche Mitteilung 2004
39. Meier JJ, Nauck MA, Schmidt WE, Gallwitz B. Diagnose einer eingeschränkten Glukosetoleranz und Diabetesprävention. Deutsches Ärzteblatt 2002; 23: A3182-3189
40. Schäfer-Graf UM, Vetter K. Screening, Diagnostik und Therapie des Gestationsdiabetes. Der Gynäkologe 2002; 35: 652-660
41. ADA. Screening for Type 2 Diabetes. Diabetes Care 2004; 27: S47-S54
42. Eckardstein vA, Schulte H, Assmann G. Risk for diabetes mellitus in middle-aged caucasian male participants of the PROCAM Study: implications for the definition of impaired fasting glucose by the American Diabetes Association. JCEM 2000; 85: 3101-3108
43. Couthinho M, Gerstein HC, Wang Y, Yusuf S. The relationship between glucose and incident cardiovascular events. Diabetes Care 1999; 22: 233-240
44. Hu FB, Stampfer MJ, Haffner SM, Solomon CG, Willet WC, Manson JE. Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes. Diabetes Care 2002; 25: 1129-1123
45. Hanefeld M. Fällt der Grenzwert? Medical Tribune 2001; 36: 3
46. Häring, HU. Pathogenesis of type II diabetes: are there common causes for insulin resistance and secretion failure? Exp Clin Endocrinol Diabetes 1999; 107: 17-23
47. Carmina E, Lobo RA. Use of fasting blood to assess the prevalence of insulin resistance in women with polycystic ovary syndrome. Fertil Steril 2004; 82: 661-665
48. Barbieri M, Rizzo MR, Manzella D, Paolisso G. Age-related insulin resistance: is it an obligatory finding? The lesson from healthy centenarians. Diabetes Metab Res Rev 2001; 17: 19-26
49. Fernandez-Real JM, Ricart W. Insulin resistance and chronic cardiovascular inflammatory syndrome. Endocrine Reviews 2003; 24: 279-301
50. Erdmann E, Hanefeld M. Glitazone - eine antidiabetische Substanzklasse aus kardiologischer Sicht. Deutsches Ärzteblatt 2004; 101: A2954-A2961
51. Goldstein BJ, Scalia R. Adiponectin: A novel adipokine linking adipocytes and vascular function. JCEM 2004; 89: 2563-2568
52. Choi KM, Lee KW, Kim SG, Park CG, Seo HS, Choi DJ, Oh DS, Baik SH. Inflammation, insulin resistance, and glucose intolerance in acute myocardial infarction patients without a previous diagnosis of diabetes mellitus. JCEM 2005; 90: 175-180
53. Bonora E, Willeit J, Kiechl S, Oberhollenzer F, Egger G, Bonadonna R, Muggeo M. Relationship between insulin and carotid atherosclerosis in the general population. Stroke 1997; 28: 1147-1152
54. Haffner SM, Williams K, Rozek MM, Stern P. Homeostasis model assessment insulin resistance in relation to 8-years of incidence of cardiovascular diseases. Diabetologia 2000; 43: 1080
55. Windler E. Die Verantwortung des Frauenarztes in der Prävention von Herz-Kreislauf-Erkrankungen. Frauenarzt 2004; 45: 735-739
56. Howard G, O'Leary DH, Zaccaro D, Haffner SM, Rewers M, Hamman R, Selby JV, Saad MF, Savage P, Bergmann R. Insulin sensitivity and atherosclerosis. Circulation 1996; 93: 1809-1817
57. Festa A, D'Agostino R, Howard G, Mykkänen L, Tracy RP, Haffner SM. Chronic subclinical inflammation as part of the insulin resistence syndrome: The Insulin Resistence Atherosclerosis Study (IRAS). Circulation 2000; 102: 42-47
58. Pyörälä M, Miettinen H, Halone P, Laakso M, Pyörälä K. Insulin resistance syndrome predicts the risk of coronary heart disease and stroke in healthy middle-aged men. Arterioscler Thromb Vasc Bio 2000; 20: 538-544
59. Bonora E, Targher G, Alberiche M, Bonadonna RC, Saggiani F, Zenere MB, Monauni T, Muggeo M. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity. Diabetes Care 2000; 23: 57-63
60. Hanley AJG, Williams K, Stern MP, Haffner SM. Homeostasis model assessment of insulin resistance in relation to the incidence of cardiovascular disease. Diabetes Care 2002; 25: 1177-1184
61. Matthaei S, Stumvoll M, Häring H-U. Thiazolidindione (Insulinsensitizer). Deutsches Ärzteblatt 2001; 98: A912-918
62. Abbasi F, Brown BW, Lamendola C, McLaughlin T, Reaven GM. Relationship between obesity, insulin resistance, and coronary heart disease risk. J Am Coll Cardiol 2002; 40: 937-943
63. Stumvoll M, Mitrakou A, Pimenta W, Jenssen T, Yki-Järvinen H, Van Heaften T, Renn W, Gerich J. Use of the oral glucose tolerance test to assess insulin release and insulin sensitivity. Diabetes Care 2000; 23: 295-301
64. Olefsky J, Farquhar JW, Reaven GM, Alto P. Relationship between fasting plasma insulin level and resistance to insulin-mediated glucose uptake in normal and diabetic subjects. Diabetes 1973; 22: 507-513
65. Norhammer A, Tenerz Ä, Nilsson G, Hamsten A, Efendic S, Rydén L, Malmberg K. Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study. Lancet 2002; 359: 2140-2144
66. Zylka-Menhorn V. Viele Herzinfarktpatienten sind unerkannte Diabetiker. Dtsch Ärzteblatt 2004; 101: A2440-2443
67. Miettinen H, Lehto S, Salomaa V, Mähönen M, Niemelä M, Haffner SM, Pyörälä K, Tuomilehto J. Impact of diabetes on mortality after the first myocardial infarction. Diabetes Care 1998; 21: 69-75
68. Bartnik M, Malmberg K, Norhammer A, Tenerz A, Öhrvik J, Ryden L. Newly detected abnormal glucose tolerance: an important predictor of long-term outcome after myocardial infarction. European Heart Journal 2004; 25: 1990-1997
69. Lenz M, Müjlhauser I. Kardiovaskuläre Risikoschätzung für eine informierte Patientenentscheidung. Med Klinik 2004; 99: 651-661
70. Bartnik M, Ryden L, Ferran R, Malmberg K, Pyörälä K, Simoons M, Standl E, Soler-Soler J, Öhrvik J. The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe. European Heart Journal 2004; 25: 1880-1890
71. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A, Pais P, Varigas J, Lisheng L. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries. Lancet 2004; 364: 937